High affinity and covalent-binding microtubule stabilizing agents show activity in chemotherapy-resistant acute myeloid leukemia cells

Cancer Letters

Volumn 368, Issue 1, 2015, Pages 97-104

  Pera, Benet ^a,b   Calvo Vidal, M Nieves ^a   Ambati, Srikanth ^b   Jordi, Michel ^c   Kahn, Alissa ^b   Díaz, J Fernando ^d   Fang, Weishuo ^e   Altmann, Karl Heinz ^c   Cerchietti, Leandro ^a   Moore, Malcolm A S ^b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c ETH ZURICH   (Switzerland)

^d CENTRO DE INVESTIGACIONES BIOLÓGICAS   (Spain)

^e INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

Acute myeloid leukemia (AML); Chemotherapy; Microtubules; P glycoprotein; Resistance

Indexed keywords

ABC TRANSPORTER; ANTINEOPLASTIC AGENT; CASPASE 3; CASPASE 7; CTX 40; CYTARABINE; DAUNORUBICIN; MICROTUBULE STABILIZING AGENT; MULTIDRUG RESISTANCE PROTEIN; PACLITAXEL; PACLITAXEL DERIVATIVE; UNCLASSIFIED DRUG; VINBLASTINE; ZAMPANOLIDE; MACROLIDE; TUBULIN MODULATOR;

ACUTE MYELOBLASTIC LEUKEMIA; ANIMAL CELL; APOPTOSIS; ARTICLE; BINDING AFFINITY; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER RESISTANCE; CELL CYCLE; CELL CYCLE ARREST; CELL PROLIFERATION; CHEMOSENSITIVITY; COLONY FORMING UNIT; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG POTENTIATION; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKEMIA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; ANALOGS AND DERIVATIVES; ANIMAL; CANCER STEM CELL; CELL CYCLE CHECKPOINT; DOSE RESPONSE; DRUG EFFECTS; DRUG RESISTANCE; HL 60 CELL LINE; METABOLISM; MICROTUBULE; PATHOLOGY; TIME;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL CYCLE CHECKPOINTS; CELL PROLIFERATION; DAUNORUBICIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; HEMATOPOIETIC STEM CELLS; HL-60 CELLS; HUMANS; LEUKEMIA, MYELOID, ACUTE; MACROLIDES; MICE; MICROTUBULES; NEOPLASTIC STEM CELLS; PACLITAXEL; TIME FACTORS; TUBULIN MODULATORS;

EID: 84940739630     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2015.07.038     Document Type: Article

References (26)

1. Ferrara F., Schiffer C.A. Acute myeloid leukaemia in adults. Lancet 2013, 381(9865):484-495.
2. Roboz G.J. Current treatment of acute myeloid leukemia. Curr. Opin. Oncol 2012, 24(6):711-719.
3. Peloquin G.L., Chen Y.B., Fathi A.T. The evolving landscape in the therapy of acute myeloid leukemia. Protein Cell 2013, 4(10):735-746.
4. Tallman M.S., Gilliland D.G., Rowe J.M. Drug therapy for acute myeloid leukemia. Blood 2005, 106(4):1154-1163.
5. Ishikawa F., et al. Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region. Nat. Biotechnol 2007, 25(11):1315-1321.
6. van den Heuvel-Eibrink M.M., et al. CD34-related coexpression of MDR1 and BCRP indicates a clinically resistant phenotype in patients with acute myeloid leukemia (AML) of older age. Ann. Hematol 2007, 86(5):329-337.
7. Wulf G.G., et al. A leukemic stem cell with intrinsic drug efflux capacity in acute myeloid leukemia. Blood 2001, 98(4):1166-1173.
8. Libby E., Hromas R. Dismounting the MDR horse. Blood 2010, 116(20):4037-4038.
9. Buey R.M., et al. Cyclostreptin binds covalently to microtubule pores and lumenal taxoid binding sites. Nat. Chem. Biol 2007, 3(2):117-125.
10. Yang C.G., et al. Overcoming tumor drug resistance with high-affinity taxanes: a SAR study of C2-modified 7-acyl-10-deacetyl cephalomannines. ChemMedChem 2007, 2(5):691-701.
11. Matesanz R., et al. Optimization of taxane binding to microtubules: binding affinity dissection and incremental construction of a high-affinity analog of paclitaxel. Chem. Biol 2008, 15(6):573-585.
12. Cai P., et al. A semisynthetic taxane Yg-3-46a effectively evades P-glycoprotein and beta-III tubulin mediated tumor drug resistance in vitro. Cancer Lett 2013, 341(2):214-223.
13. Field J.J., et al. Zampanolide, a potent new microtubule-stabilizing agent, covalently reacts with the taxane luminal site in tubulin alpha, beta-heterodimers and microtubules. Chem. Biol 2012, 19(6):686-698.
14. Zurwerra D., et al. Total synthesis of (-)-zampanolide and structure-activity relationship studies on (-)-dactylolide derivatives. Chemistry (Easton) 2012, 18(52):16868-16883.
15. Chung K.Y., et al. Enforced expression of an Flt3 internal tandem duplication in human CD34+ cells confers properties of self-renewal and enhanced erythropoiesis. Blood 2005, 105(1):77-84.
16. Lobert S., Hiser L., Correia J.J. Expression profiling of tubulin isotypes and microtubule-interacting proteins using real-time polymerase chain reaction. Methods Cell Biol 2010, 95:47-58.
17. Breems D.A., et al. Frequency analysis of human primitive haematopoietic stem cell subsets using a cobblestone area forming cell assay. Leukemia 1994, 8(7):1095-1104.
18. Moore M.A., et al. Constitutive activation of Flt3 and STAT5A enhances self-renewal and alters differentiation of hematopoietic stem cells. Exp. Hematol 2007, 35(4 Suppl. 1):105-116.
19. Chou T.C., Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul 1984, 22:27-55.
20. Berenbaum M.C. The expected effect of a combination of agents: the general solution. J. Theor. Biol 1985, 114(3):413-431.
21. Koeffler H.P., et al. An undifferentiated variant derived from the human acute myelogenous leukemia cell line (KG-1). Blood 1980, 56(2):265-273.
22. Wang H., et al. Methylation of SFRP5 is related to multidrug resistance in leukemia cells. Cancer Gene Ther 2014, 21(2):83-89.
23. Bacherikov V.A., et al. Potent antitumor N-mustard derivatives of 9-anilinoacridine, synthesis and antitumor evaluation. Bioorg. Med. Chem. Lett 2004, 14(18):4719-4722.
24. Eldjerou L.K., et al. An in vivo model of double-unit cord blood transplantation that correlates with clinical engraftment. Blood 2010, 116(19):3999-4006.
25. Kiyoi H., et al. Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product. Leukemia 1998, 12(9):1333-1337.
26. Patel J.P., et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N. Engl. J. Med 2012, 366(12):1079-1089.